Natera CEO Steven Chapman sells $526k in common stock

Oruka Therapeutics CEO Lawrence Otto Klein sold approximately $2.09 million worth of the company's stock on October 1, 2026, as reported by a recent SEC filing. This sale was conducted in line with a pre-established Rule 10b5-1 trading plan. The sale comprised multiple transactions, totaling 25,000 shares. Klein sold 16,246 shares at an average price of $83.40 per share, with each share priced between $82.75 and $83.73.

An additional 8,554 shares were sold at an average price of $84.03, ranging from $83.75 to $84.69. A smaller block of 200 shares was sold at an average price of $84.78, with individual prices between $84.75 and $84.81. Before selling these shares, Klein had acquired 25,000 shares through the exercise of an employee warrant, a purchase that was valued at $195,000.

As a result of these transactions, Lawrence Otto Klein now directly owns 923,128 shares of Oruka Therapeutics common stock, in addition to benefiting from 1,528,513 derivative securities in the form of employee warrants. Oruka Therapeutics recently reported positive results from its Phase 2a EVERLAST-A trial for ORKA-001, demonstrating significant improvements in efficacy.

The trial showed an increase in the PASI 100 response rate to 71.4% at Week 28, up from 63.5% at Week 16, and an 87.3% PASI 90 rate. These results indicate ongoing progress six months post-treatment. H.C. Wainwright maintains a Buy rating on Oruka Therapeutics with a price target of $120, reflecting confidence in the company’s trial outcomes.

Additionally, Oruka Therapeutics appointed Todd Edwards as their Chief Commercial Officer, leveraging his extensive commercial leadership experience in immunology and dermatology to bolster their commercial strategy. This information was compiled with AI assistance and reviewed by an editor.